DGAP-News: Viridax collaborates with Slovenian partner on novel antimicrobials

Viridax Corporation  / Key word(s): Alliance/Miscellaneous

25.10.2010 08:32 
---------------------------------------------------------------------------

October 25, 2010 - Viridax Corporation (FSE:VRC) ('Viridax' or the
'Company') is pleased to report that the Company has completed an important
step in the manufacturing process for its first product for the treatment
of Ventilator Associated Pneumonia ('VAP'), as incited by
Methicillin-Resistant Staphylococcus aureus ('MRSA'). Viridax completed the
development and evaluation of an important purification step for its
manufacturing process by working with BIA Separations, Inc., a
manufacturing development partner in Ljubljana, Slovenia.

Viridax is developing genetically-selected versions of naturally-occurring
viruses, called bacteriophage, to treat diseases where antibiotic-resistant
bacteria are becoming an increasing problem, such as staph infections and
tuberculosis. Bacteriophage are viruses that are specifically developed for
the purpose of parasitizing and killing bacteria.

The primary risk factor for hospital-acquired bacterial pneumonia is
mechanical ventilation. Between 85,000 and 100,000 patients die each year
just in the U.S.A. from various hospital infections, with MRSA being
recognized as one of the leading causes. It is estimated that more than 10
percent of all hospital patients in the United States develop an infection,
leading to an increase of about US $5 billion in annual healthcare costs.

Viridax plans to continue development, manufacturing and preclinical
testing this year, and then begin first human clinical trials in late 2011.
With more antibiotics becoming less effective, the power and clinical
utility of bacteriophage are being rediscovered. Richard Honour, PhD,
Vice-President of Research and Development at Viridax commented that:
'Viridax is uniquely positioned to address one of the most serious problems
associated with global health care in general and hospitalization in
particular. Our objective is to complete development of the bacteriophage,
secure regulatory approval and market these products in co-operation with a
major pharmaceutical company on a basis designed to enhance shareholder
values.'


About Viridax Corporation

Viridax Corporation was formed to develop new products for the treatment of
respiratory and systemic infections incited by Staphylococcus aureus (S.
aureus) and other Staphylococcal species. The management of Viridax is
primarily focused on providing safe, effective and affordable treatment
alternatives to conventional antibiotics, and to demonstrate the clinical
utility of the Viridax products by substantially reducing the incidence,
prevalence, morbidity and mortality of targeted bacterial infections in
both community and hospital settings. The Company plans to develop products
that are less toxic and more efficacious than conventional antibiotics, and
at lower cost, but that will target antibiotic-resistant bacteria, thus
providing access to extensive global markets. Management intends to
manufacture and evaluate the initial S. aureus bacteriophage product in
compliance with US Food and Drug Administration (FDA) guidelines to assure
approval by US and international regulatory authorities.


On behalf of the Board of Directors

Viridax Corporation
Richard C. Honour, PhD.
Vice-President and Chairman of the Board


FORWARD-LOOKING STATEMENTS

Statements in this document which are not purely historical are
'forward-looking statements', including any statements regarding the
intent, belief or current expectations of Viridax Corporation and members
of its management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that such forward-looking
statements are not guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from those
contemplated by such forward-looking statements. Important factors
currently known to management that could cause actual results to differ
materially from those in forward-looking statements include, among others,
material changes in the global capital markets that may impact negatively
on the Company's ability to secure the working capital required to complete
the development and production of its pharmaceutical products on a timely
basis, the competitive nature of the biopharmaceutical industry and the
ability of the Company to attract the personnel required to efficiently
execute the Company's business plan. Forward looking statements are made
based on management's beliefs, estimates and opinions on the date the
statements are made and the Company undertakes no obligation to update
forward-looking statements if these beliefs, estimates and opinions or
other circumstances should change, except as updates may be required by
applicable law. Such forward-looking statements reflect our current views
with respect to future events and are subject to certain risks,
uncertainties and assumptions, including, the risks and uncertainties
outlined in our most recent financial statements. Although the Company
believes that the plans, expectations and intentions contained in this news
release are reasonable, there can be no assurance those plans, expectations
or intentions will prove to be accurate. Investors should consider all of
the information set forth herein. This news release shall not constitute an
offer to sell or the solicitation of an offer to buy securities nor shall
there be any sale of securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to qualification under the
applicable securities laws of any such jurisdiction.



Richard C. Honour, PhD.
Vice-President and Chairman of the Board
Tel: (425) 772-1473 
Email: rhono@viridax.com

Website: www.viridax.com




25.10.2010 08:32 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases. 
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------